News
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)
Lonza erzielt ein starkes Ergebnis in 2021 mit 20% Umsatzwachstum (kWk)
Lonza Delivers Strong 2021 performance with 20% CER Sales Growth
DGAP-News: Abivax 2022 Financial Communication Calendar
DGAP-News: Abivax Finanzkalender 2022
DGAP-News: Abivax's phase 1/2 clinical study results of ABX196 in liver cancer to be presented on Jan. 21, at ASCO GI Cancers Symposium 2022
DGAP-News: Abivax präsentiert die Ergebnisse der klinischen Phase 1/2 Studie mit ABX196 zur Behandlung von Leberkrebs am 21. Januar auf dem ASCO GI Cancers Symposium 2022
DGAP-News: Abivax receives EMA Scientific Advice supportive of moving ABX464 into phase 3 clinical testing in ulcerative colitis
DGAP-News: Abivax: Ergebnis der wissenschaftlichen Beratungen der europ. Arzneimittelbehörde (EMA) unterstützt die Überführung von ABX464 in die klinische Phase-3-Testung zur Behandlung von Colitis ulcerosa
DGAP-News: Abivax präsentiert auf der J.P. Morgan 40th Annual Healthcare Conference
DGAP-News: Abivax to present at the J.P. Morgan 40th Annual Healthcare Conference
DGAP-News: Abivax erhält Feedback der US-Amerikanischen Zulassungsbehörde mit Guidance zur Überführung von ABX464 in die klinische Phase-3-Testung
DGAP-News: Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis
DGAP-News: Abivax's phase 1/2 clinical study results of ABX196 in liver cancer show good tolerability and promising signals of clinical benefit and were selected for presentation at the ASCO GI Cancers Symposium
DGAP-News: Abivax' Phase-1/2-Studienergebnisse mit ABX196 zur Behandlung von Leberkrebs zeigen gute Sicherheit und vielversprechende Anzeichen klinischen Nutzens ...
3 Stocks Set to Benefit from Cooling Inflation Trends
Here's a little twist for those who like to focus on fundamentals and economic forces when predicting the stock market. When inflation runs hot, it benefits stocks overall, and the opposite is
3 Stocks Set to Benefit from Cooling Inflation Trends
Here's a little twist for those who like to focus on fundamentals and economic forces when predicting the stock market. When inflation runs hot, it benefits stocks overall, and the opposite is
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor’s stock
Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
As a new regime and phase begin for the market and economy, after the FED cut interest rates by a surprising 50bps last Wednesday, several new opportunities and sector bull and bear markets might
Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
As a new regime and phase begin for the market and economy, after the FED cut interest rates by a surprising 50bps last Wednesday, several new opportunities and sector bull and bear markets might